Menu Search
Equities

American Well Corp

AMWL:NYQ

American Well Corp

Actions
Health CareHealth Care Providers
  • Price (USD)9.92
  • Today's Change0.09 / 0.92%
  • Shares traded48.79k
  • 1 Year change-61.55%
  • Beta1.0429
Data delayed at least 15 minutes, as of Sep 20 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform0
Hold11
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for American Well Corp have a median target of 11.00, with a high estimate of 66.00 and a low estimate of 8.00. The median estimate represents a 10.89% increase from the last price of 9.92.
High565.3%66.00
Med10.9%11.00
Low-19.4%8.00

Earnings history & estimates in USD

On Jul 31, 2024, American Well Corp reported 2nd quarter 2024 losses of -3.36 per share. This result exceeded the -3.98 consensus loss of the 12 analysts covering the company and exceeded last year's 2nd quarter results by 49.09%.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate+1.22%
American Well Corp reported annual 2023 losses of -47.60 per share on Feb 14, 2024.
Average growth rate-38.09%
More ▼

Revenue history & estimates in USD

American Well Corp had 2nd quarter 2024 revenues of 62.79m. This bettered the 61.61m consensus of the 11 analysts covering the company. This was 1.89% below the prior year's 2nd quarter results.
Average growth rate+0.75%
American Well Corp had revenues for the full year 2023 of 259.05m. This was 6.55% below the prior year's results.
Average growth rate+2.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.